These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Toccaceli F; Rosati S; Scuderi M; Iacomi F; Picconi R; Laghi V Hepatogastroenterology; 1998; 45(23):1748-52. PubMed ID: 9840140 [TBL] [Abstract][Full Text] [Related]
26. The interferons and their use in condyloma acuminata. Browder JF; Araujo OE; Myer NA; Flowers FP Ann Pharmacother; 1992 Jan; 26(1):42-5. PubMed ID: 1376628 [TBL] [Abstract][Full Text] [Related]
27. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Simsek H; Savas C; Akkiz H; Telatar H Dermatology; 1996; 193(1):65-6. PubMed ID: 8864627 [TBL] [Abstract][Full Text] [Related]
28. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Kumar KS; Russo MW; Borczuk AC; Brown M; Esposito SP; Lobritto SJ; Jacobson IM; Brown RS Am J Gastroenterol; 2002 Sep; 97(9):2432-40. PubMed ID: 12358269 [TBL] [Abstract][Full Text] [Related]
29. Potential mechanisms of interferon neurotoxicity. Bender CM; Monti EJ; Kerr ME Cancer Pract; 1996; 4(1):35-9. PubMed ID: 8788769 [TBL] [Abstract][Full Text] [Related]
30. Parkinsonism in Patients With Chronic Hepatitis C Treated With Interferons: Case Reports and Review of the Literature. Wangensteen KJ; Krawitt EL; Hamill RW; Boyd JT Clin Neuropharmacol; 2016; 39(1):1-5. PubMed ID: 26757310 [TBL] [Abstract][Full Text] [Related]
31. Potentiation of warfarin by interferon. Adachi Y; Yokoyama Y; Nanno T; Yamamoto T BMJ; 1995 Jul; 311(7000):292. PubMed ID: 7543311 [No Abstract] [Full Text] [Related]
32. Prospects for the medical use of interferon in 1984. Postic B; Arroyo JC Henry Ford Hosp Med J; 1984; 32(2):116-22. PubMed ID: 6210270 [No Abstract] [Full Text] [Related]